System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Epublish

PubMed: 41322956 DOI: 10.1016/j.euros.2025.10.023

Clinical and Pathological Features Associated with Chromophobe Renal Cell Carcinoma Recurrence: Analysis from a Nationwide Cohort.

Eur Urol Open Sci 82:185-191

Authors: Arthur Peyrottes, Edouard Auclin, Marc-Olivier Timsit, Nicolas Branger, Nicolas Doumerc, Thibaut Waeckel, Pierre Bigot, Louis Surlemont, Sophie Knipper, Géraldine Pignot, Frank Bruyère, Alexis Fontenil, Bastien Parier, Cécile Champy, Morgan Rouprêt, Jean-Jacques Patard, François Henon, Gaëlle Fiard, Julien Guillotreau, Jean-Baptiste Beauval, Constance Michel, Simon Bernardeau, Fayek Taha, Richard Mallet, Frederic Panthier, Laurent Guy, Louis Vignot, Zine-Eddine Khene, Jean-Christophe Bernhard, Arnaud Méjean, François Audenet

Affiliations

  • Department of Urology, Hôpital Européen Georges Pompidou, AP-HP, Université Paris Cité, Paris, France.
  • Department of Urology, CHU Saint-Louis, AP-HP, Université Paris Cité, Paris, France.
  • Oncology Department, Hôpital Européen Georges Pompidou, AP-HP, Université Paris Cité, Paris, France.
  • Department of Urology, Institut Paoli Calmettes, Marseille, France.
  • Department of Urology, CHU Toulouse, Toulouse, France.
  • Department of Urology, CHU Caen, Caen, France.
  • Department of Urology, CHU Angers, Angers, France.
  • Department of Urology, CHU Rouen, Rouen, France.
  • Department of Urology, CHU Tours, Tours, France.
  • Department of Urology, CHU Nîmes, Nîmes, France.
  • Department of Urology, CHU Bicêtre, Paris, France.
  • Department of Urology, Hôpital Henri Mondor, INSERM, Clinical Investigation Center 1430, Créteil, France.
  • Department of Urology, GRC 5 Predictive Onco-Uro, AP-HP, CHU Pitié-Salpêtriere, Sorbonne University, Paris, France.
  • Department of Urology, CH Mont-de-Marsan, Mont-de-Marsan, France.
  • Department of Urology, CHU Lille, Lille, France.
  • Department of Urology, CHU Grenoble, Grenoble, France.
  • Department of Urology, Clinique Pasteur, Toulouse, France.
  • Department of Urology, Clinique Croix du Sud, Toulouse, France.
  • Department of Urology, Hôpital Saint-Joseph, Paris, France.
  • Department of Urology, CHU Poitiers, Poitiers, France.
  • Department of Urology, CHU Reims, Reims, France.
  • Department of Urology, Polyclinique Francheville, Périgueux, France.
  • Department of Urology, CHU Tenon, Paris, France.
  • Department of Urology, CHU Clermont-Ferrand, Clermont-Ferrand, France.
  • Department of Urology, CHU Nice, Nice, France.
  • Department of Urology, CHU Rennes, Rennes, France.
  • Department of Urology, CHU Bordeaux, Bordeaux, France.

Abstract

BACKGROUND AND OBJECTIVE

Chromophobe renal cell carcinoma (chRCC) is a rare renal malignancy with a generally favourable prognosis. However, a subset of patients experiences recurrence, which remains poorly characterised. This study aims to identify the clinicopathological factors associated with recurrence in chRCC, describe the timing and anatomical patterns of recurrence, and develop a predictive model to guide surveillance strategies.

METHODS

We conducted a multicentre retrospective cohort study using data from the French UroCCR database, including patients treated surgically for nonmetastatic chRCC between 2010 and 2024. Clinicopathological features, recurrence-free survival (RFS), cancer-specific survival, and overall survival were analysed. Kaplan-Meier survival curves and multivariable Cox proportional-hazard models were used to assess prognostic factors.

KEY FINDINGS AND LIMITATIONS

Among the included 683 patients, 43 (6.3%) developed recurrence, with median RFS of 142 mo (95% confidence interval [CI] 121-not reached). Local recurrence was observed in 30 patients, while 18 developed distant metastases, predominantly in the retroperitoneal lymph nodes and lungs. Male sex (hazard ratio [HR] 3.1, 95% CI 1.27-7.54, p = 0.01), locally advanced disease (HR 1.94, 95% CI 1.02-3.84, p = 0.05), positive surgical margins (HR 3.03, 95% CI 1.4-6.56, p = 0.005), and lymphovascular invasion (HR 2.08, 95% CI 1.01-4.38, p = 0.05) were independently associated with recurrence. Limitations include the absence of a central pathological review and of standardised recurrence management strategies across centres.

CONCLUSIONS AND CLINICAL IMPLICATIONS

This study provides novel insights into the recurrence patterns of chRCC, highlighting the key prognostic factors. The proposed predictive model was designed to aid clinicians in identifying high-risk patients, optimising follow-up intensity, and guiding therapeutic decisions.

PATIENT SUMMARY

We studied a rare kidney cancer type, called chromophobe renal cell carcinoma (chRCC), to understand why some patients experience recurrence. We found that being male, having advanced disease, or some aggressive pathological characteristics increased the risk of cancer coming back. Our results suggest that doctors should monitor certain patients more closely after surgery. This research may help improve long-term follow-up and treatment plans for patients with chRCC. While certain factors are associated with a higher risk of recurrence, it is important to note that chromophobe renal cell carcinoma generally has a favourable prognosis, and the absolute risk of recurrence remains low for most patients.

MeSH

Cells, Margins Of Excision, Neoplasms, Carcinoma, Renal Cell, Lymph, Therapeutics, Prognosis